NASDAQ · PRFX

PRF Technologies Ltd.

$1.14 -$0.01 (-1.30%) 1D After hours

Key Metrics

$3.50M
Market cap
P/E · TTM
$17.00K
Revenue · TTM
−$5.02M
Net income
EPS · TTM $-66.07
Dividend yield
Free cash flow −$3.96M
Beta · 1Y 2.10
EBITDA · TTM −$5.00M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 29 high, the share price fell 68%.

    Peak close $3.54 on Jan 29; trough close $1.14 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -68%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 15
    The stock moved +83.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 15
  • May 29
    The stock moved +119.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 29

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$3.50M
Enterprise value
Shares outstanding3.0M
52-wk range$0.61 – $7.95
Avg volume · 20D556.6K
Net cash
Book value / share$112.40
ExchangeNASDAQ
About PRF Technologies Ltd.
IPO dateSep 1, 2020
Employees6

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S205.77
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -29,494.1%
Net -29,541.2%
FCF -23,276.5%
ROE / ROIC -96.9% · -92.7%

Financial Health

Current ratio1.78
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$1.91M

Cash Flow · TTM

Operating CF −$3.96M
Capex −$2.00K
Free cash flow −$3.96M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-7.6
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings